US2018161347A1PendingUtilityA1
Methods and materials for killing hiv infected cells
Assignee: MAYO FOUND MEDICAL EDUCATION & RESPriority: Apr 20, 2015Filed: Apr 20, 2016Published: Jun 14, 2018
Est. expiryApr 20, 2035(~8.7 yrs left)· nominal 20-yr term from priority
A61K 45/06A61K 38/2013A61K 31/21A61P 31/18A61K 31/635A61K 31/52A61K 31/5377A61K 31/536A61K 31/675A61K 31/505A61K 31/4418A61K 31/47A61K 31/5365A61K 31/513A61K 31/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
Claims
exact text as granted — not AI-modified1 . A method for killing HIV infected cells within a human infected with HIV, wherein said method comprises:
(a) administering a Bcl-2 inhibitor to said human, and (b) administering a latency reversing agent to said human.
2 . The method of claim 1 , wherein said cells are CD4 + T cells.
3 . The method of claim 1 , wherein said Bcl-2 inhibitor is ABT-199.
4 . The method of claim 1 , wherein said latency reversing agent is selected from the group consisting of an HDAC inhibitor, a phorbol ester, IL-2, and a bromodomain inhibitor.Join the waitlist — get patent alerts
Track US2018161347A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.